XML 46 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Product Sales (Tables)
 12 Months Ended
Dec. 31, 2019
Revenues [Abstract]  
Schedule of Product Sales
Net product sales consist of the following:
 
 
Year Ended December 31,
Net Product Sales in the United States
 
2019
 
2018
 
2017
EYLEA
 
$
4,644.2

 
$
4,076.7

 
$
3,701.9

Libtayo
 
175.7

 
14.8

 
—

ARCALYST
 
14.5

 
14.7

 
16.6

 
 
$
4,834.4

 
$
4,106.2

 
$
3,718.5


Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which were previously terminated):
 
 
Year Ended December 31,
Bayer EYLEA Collaboration Revenue
 
2019
 
2018
 
2017
Regeneron's net profit in connection with commercialization of EYLEA outside the United States
 
$
1,091.4

 
$
992.3

 
$
802.3

Reimbursement of EYLEA development expenses
 
23.0

 
11.2

 
13.3

Other
 
74.4

 
73.6

 
58.7

 
 
$
1,188.8

 
$
1,077.1

 
$
874.3


The collaboration revenue we earned from Sanofi is detailed below:
 
 
Year Ended December 31,
Sanofi Collaboration Revenue
 
2019
 
2018
 
2017
Antibody:
 
 
 
 
 
 
Reimbursement of research and development expenses
 
$
277.7

 
$
265.3

 
$
508.4

Reimbursement of commercialization-related expenses
 
479.9

 
417.2

 
368.8

Reimbursement for manufacturing of commercial supplies
 
206.7

 
127.6

 
35.1

Regeneron's share of profits (losses) in connection with commercialization of antibodies
 
209.3

 
(227.0
)
 
(442.6
)
Other
 
(1.5
)
 
(24.1
)
 
84.0

Total Antibody
 
1,172.1

 
559.0

 
553.7

Immuno-oncology:
 
 
 
 
 
 
Reimbursement of research and development expenses
 
163.0

 
311.8

 
240.0

Reimbursement of commercialization-related expenses
 
10.3

 
8.9

 
7.0

Amounts recognized in connection with up-front payments received
 
92.7

 
243.8

 
80.0

Other
 
(11.3
)
 
(12.4
)
 
(3.5
)
Total Immuno-oncology
 
254.7

 
552.1

 
323.5

 
 
$
1,426.8

 
$
1,111.1

 
$
877.2
Schedules of Concentration of Risk, by Risk Factor
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December 31, 2019, 2018, and 2017. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Besse Medical, a subsidiary of AmerisourceBergen Corporation
57
%
 
56
%
 
51
%
McKesson Corporation
33
%
 
36
%
 
29
%
Curascript SD Specialty Distribution, a subsidiary of Express Scripts
**

 
**

 
19
%
 
 
 
 
 
 
** Sales to Curascript SD Specialty Distribution represented less than 10% of total gross product revenue during the period.
Sales Related Deductions Activity
The following table summarizes the provisions, and credits/payments, for sales-related deductions for the years ended December 31, 2019, 2018, and 2017.
 
Rebates, Chargebacks, and Discounts
 
Distribution-
Related Fees
 
Other Sales-
Related Deductions
 
Total
Balance as of December 31, 2016
$
12.7

 
$
29.5

 
$
3.6

 
$
45.8

Provisions
167.8

 
194.1

 
46.4

 
408.3

Credits/payments
(150.6
)
 
(189.5
)
 
(28.7
)
 
(368.8
)
Balance as of December 31, 2017
29.9

 
34.1

 
21.3

 
85.3

Provisions
223.4

 
211.0

 
44.5

 
478.9

Credits/payments
(212.2
)
 
(203.1
)
 
(57.5
)
 
(472.8
)
Balance as of December 31, 2018
41.1

 
42.0

 
8.3

 
91.4

Provisions
423.2

 
242.9

 
61.8

 
727.9

Credits/payments
(384.0
)
 
(238.5
)
 
(40.7
)
 
(663.2
)
Balance as of December 31, 2019
$
80.3

 
$
46.4

 
$
29.4

 
$
156.1